What's New in Guidelines

Osimertinib is recommended by NICE for EGFR mutation-positive unresectable locally advanced NSCLC only after prior platinum-based chemoradiotherapy has been completed, making it a sequential rather than first-line treatment option Confirm EGFR mutation status (exon…

Rozanolixizumab is recommended as an option for treating antibody-positive generalised myasthenia gravis (gMG) in adults—consider as an add-on therapy for patients with inadequate response to standard immunosuppressive treatments or acetylcholinesterase inhibitors. Treatment eligibility requires…

AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving clinical workflow efficiency in busy cardiology services. AI tools should be used…

Establish multidisciplinary team review at diagnosis and at key developmental stages (infancy, pre-school, school age, adolescence) to monitor for complications including spinal stenosis, foramen magnum stenosis, and limb alignment issues requiring early intervention Screen…

Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part of a comprehensive cardiovascular risk management strategy alongside standard therapies (statins, ACE…

Zanidatamab is recommended by NICE as an option for HER2-positive advanced biliary tract cancer only after 1 or more prior lines of systemic treatment, making it a second-line or later therapy option for eligible…

Oxybutynin is effective for neurogenic detrusor overactivity in patients aged 6+ years with spinal cord injury or spina bifida—consider as first-line antimuscarinic therapy for managing symptoms and reducing incontinence episodes in this population. Monitor…

Appraisal terminated: Inebilizumab appraisal was terminated by NICE; refer to current NICE guidance and your local formulary for up-to-date treatment recommendations for IgG4-related disease rather than relying on this assessment. Check local commissioning: Verify…

Test for BRAF V600E mutation in patients with advanced NSCLC before considering encorafenib plus binimetinib, as this combination is only recommended for mutation-positive disease and forms part of the diagnostic pathway for treatment selection.…

Use digital asthma self-management tools (apps, web platforms, wearables) as adjuncts to standard care to help patients monitor symptoms, track triggers, and improve medication adherence—particularly beneficial for patients with poor control or limited access…

Belantamab mafodotin combined with bortezomib and dexamethasone is recommended for previously treated multiple myeloma patients; consider this regimen when standard retreatment options have been exhausted or are unsuitable. Monitor for keratopathy (corneal toxicity) as…

Sodium zirconium cyclosilicate is recommended as a treatment option for hyperkalaemia in adults and can be used for both acute management and chronic maintenance therapy to reduce serum potassium levels. The medication works in…

Indicated for IDH-mutant gliomas post-surgery: Vorasidenib is recommended for astrocytoma or oligodendroglioma with confirmed IDH1 or IDH2 mutations in patients aged 12+ following surgical resection—ensure mutation status is confirmed before initiating treatment. Timing of…

Ripretinib is recommended as an option for adults with advanced gastrointestinal stromal tumours who have received 3 or more prior kinase inhibitors – use this in treatment-resistant cases where standard sequential therapy (imatinib, sunitinib,…

Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant pembrolizumab to improve outcomes compared to surgery alone. Consider patient eligibility carefully,…

Consider transvenous embolisation in patients with spontaneous intracranial hypotension confirmed to have a cerebrospinal fluid–venous fistula, as it offers a targeted intervention when conservative management has failed. Ensure multidisciplinary team assessment including neurology and…

This NICE publication is marked as a terminated appraisal, so it functions as a status notice rather than an active treatment recommendation for routine care. If reviewing spesolimab for generalised pustular psoriasis, check the…

Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals to secondary care and enabling earlier treatment initiation. Implement these technologies as…

Initial assessment in primary care: Offer semen analysis to men and check ovulation status (via progesterone blood test on day 21 of cycle) in women before referral to specialist services, to streamline secondary care…

Fezolinetant is recommended as an option for moderate to severe vasomotor symptoms (hot flushes and night sweats) in menopausal women when hormone replacement therapy is contraindicated, not tolerated, or declined Assess symptom severity and…

GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line to reduce exacerbation risk and asthma death. Biologics update: dupilumab, tezepelumab, and…

GOLD 2025 updates COPD diagnosis criteria: spirometry FEV1/FVC

This EHA guideline addresses 2023 EHA Guidelines on the Management of Myeloma in Haematology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This EMA guideline addresses EMA Reflection Paper on Extrapolation of Efficacy in Oncology in Oncology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This EMA guideline addresses EMA Guideline on Clinical Investigation of Medicinal Products for Heart Failure in Cardiology / Cardiovascular. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This ESPGHAN guideline addresses 2022 ESPGHAN Guidelines on Coeliac Disease Diagnosis in Gastroenterology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This ERA guideline addresses 2022 ERA Guidelines on the Management of Chronic Kidney Disease in Nephrology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This EAN guideline addresses 2022 EAN/EFNS Guidelines on Dementia Diagnosis and Management in Neurology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This EAN guideline addresses 2022 EAN Guidelines on Epilepsy Management in Adults in Neurology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This EAN guideline addresses 2023 EAN Guidelines on the Management of Multiple Sclerosis in Neurology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This ESCMID guideline addresses 2022 ESCMID Guidelines on Candidaemia and Invasive Candidiasis in Infectious Disease. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This ESCMID guideline addresses 2021 ESCMID Guidelines for the Management of Community-acquired Pneumonia in Respiratory / COPD / Asthma. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This EULAR guideline addresses 2023 EULAR Recommendations for Systemic Lupus Erythematosus in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This EULAR guideline addresses 2023 EULAR Recommendations for the Management of Gout in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

This EULAR guideline addresses 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in routine practice.

Covers screening recommendations for average-risk and high-risk individuals • Provides guidance on diagnostic staging and pretreatment evaluation • Addresses surgical and neoadjuvant/adjuvant treatment approaches based on tumor stage • Discusses metastatic disease management including…